Amarin Ducks Securities Action Over Vascepa Denial
By Cara Salvatore ( July 2, 2015, 4:23 PM EDT) -- A New Jersey federal judge has dismissed a securities class action against biopharmaceuticals maker Amarin Corp. PLC that claimed it artificially inflated its stock price before a U.S. Food and Drug Administration panel denied expanding the use of its fish oil drug Vascepa to treat more adults with high triglycerides....
Law360 is on it, so you are, too.
A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.
A Law360 subscription includes features such as
- Daily newsletters
- Expert analysis
- Mobile app
- Advanced search
- Judge information
- Real-time alerts
- 450K+ searchable archived articles
And more!
Experience Law360 today with a free 7-day trial.